These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 22410449)

  • 21. Early-onset parkinsonism with dystonia. Clinical and biochemical differences from hereditary progressive dystonia or DOPA-responsive dystonia.
    Furukawa Y; Mizuno Y; Narabayashi H
    Adv Neurol; 1996; 69():327-37. PubMed ID: 8615147
    [No Abstract]   [Full Text] [Related]  

  • 22. SNCA locus duplication carriers: from genetics to Parkinson disease phenotypes.
    Mutez E; Leprêtre F; Le Rhun E; Larvor L; Duflot A; Mouroux V; Kerckaert JP; Figeac M; Dujardin K; Destée A; Chartier-Harlin MC
    Hum Mutat; 2011 Apr; 32(4):E2079-90. PubMed ID: 21412942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Dystonia preceding dopa-responsive parkinsonism--heterogeneous clinical features].
    Miwa H; Mizuno Y
    No To Shinkei; 1996 Feb; 48(2):149-54. PubMed ID: 8865694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SCA2 presenting as levodopa-responsive parkinsonism in a young patient from the United Kingdom: a case report.
    Wilkins A; Brown JM; Barker RA
    Mov Disord; 2004 May; 19(5):593-5. PubMed ID: 15133829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.
    Rascol O; Lees AJ; Senard JM; Pirtosek Z; Brefel C; Montastruc JL; Fuell D
    Adv Neurol; 1996; 69():531-4. PubMed ID: 8615176
    [No Abstract]   [Full Text] [Related]  

  • 26. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?
    Clarke CE
    Mov Disord; 2004 May; 19(5):491-8. PubMed ID: 15133811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Arg(184)His mutant GTP cyclohydrolase I, causing recessive hyperphenylalaninemia, is responsible for dopa-responsive dystonia with parkinsonism: a case report.
    Kikuchi A; Takeda A; Fujihara K; Kimpara T; Shiga Y; Tanji H; Nagai M; Ichinose H; Urano F; Okamura N; Arai H; Itoyama Y
    Mov Disord; 2004 May; 19(5):590-3. PubMed ID: 15133828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopaminergic agonists in the treatment of Parkinson's disease: a review.
    Piccoli F; Riuggeri RM
    J Neural Transm Suppl; 1995; 45():187-95. PubMed ID: 8748625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Initiation of treatment in Parkinson disease].
    Ghika J
    Praxis (Bern 1994); 1995 Sep; 84(38):1018-20. PubMed ID: 7481298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism.
    Schwarz J; Tatsch K; Gasser T; Arnold G; Pogarell O; Künig G; Oertel WH
    Mov Disord; 1998 Jan; 13(1):16-9. PubMed ID: 9452320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopa-responsive camptocormia in a patient with multiple system atrophy.
    Song IU; Kim JS; Lee KS
    Parkinsonism Relat Disord; 2008; 14(2):161-3. PubMed ID: 17433754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expanding the clinical phenotype of SNCA duplication carriers.
    Nishioka K; Ross OA; Ishii K; Kachergus JM; Ishiwata K; Kitagawa M; Kono S; Obi T; Mizoguchi K; Inoue Y; Imai H; Takanashi M; Mizuno Y; Farrer MJ; Hattori N
    Mov Disord; 2009 Sep; 24(12):1811-9. PubMed ID: 19562770
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopa-responsive parkinsonism phenotype of spinocerebellar ataxia type 2.
    Lu CS; Wu Chou YH; Yen TC; Tsai CH; Chen RS; Chang HC
    Mov Disord; 2002 Sep; 17(5):1046-51. PubMed ID: 12360557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [L-dopa effective parkinsonism appeared after shunt revision of the aqueductal stenosis: report of two cases].
    Ochiai H; Yamakawa Y; Miyata S; Kawasoe T
    No To Shinkei; 2000 May; 52(5):425-9. PubMed ID: 10845212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. L-dopa slows the progression of familial parkinsonism.
    Gwinn-Hardy K; Evidente VG; Waters C; Muenter MD; Hardy J
    Lancet; 1999 May; 353(9167):1850-1. PubMed ID: 10359414
    [No Abstract]   [Full Text] [Related]  

  • 36. A 6.4 Mb duplication of the α-synuclein locus causing frontotemporal dementia and Parkinsonism: phenotype-genotype correlations.
    Kara E; Kiely AP; Proukakis C; Giffin N; Love S; Hehir J; Rantell K; Pandraud A; Hernandez DG; Nacheva E; Pittman AM; Nalls MA; Singleton AB; Revesz T; Bhatia KP; Quinn N; Hardy J; Holton JL; Houlden H
    JAMA Neurol; 2014 Sep; 71(9):1162-71. PubMed ID: 25003242
    [TBL] [Abstract][Full Text] [Related]  

  • 37. L-dopa responsive parkinsonism secondary to a subdural haematoma.
    Ellul MA; Cross J; Barker RA
    J Clin Neurosci; 2013 Jul; 20(7):1022-4. PubMed ID: 23618681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early-onset parkinsonism caused by alpha-synuclein gene triplication: Clinical and genetic findings in a novel family.
    Olgiati S; Thomas A; Quadri M; Breedveld GJ; Graafland J; Eussen H; Douben H; de Klein A; Onofrj M; Bonifati V
    Parkinsonism Relat Disord; 2015 Aug; 21(8):981-6. PubMed ID: 26077166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Schizophrenia as a prodromal symptom in a patient harboring SNCA duplication.
    Takamura S; Ikeda A; Nishioka K; Furuya H; Tashiro M; Matsushima T; Li Y; Yoshino H; Funayama M; Morinobu S; Hattori N
    Parkinsonism Relat Disord; 2016 Apr; 25():108-9. PubMed ID: 26880146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subthalamic deep brain stimulation for a Parkinson's disease patient with duplication of SNCA.
    Shimo Y; Natori S; Oyama G; Nakajima M; Ishii H; Arai H; Hattori N
    Neuromodulation; 2014 Jan; 17(1):102-3. PubMed ID: 23441980
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.